headaches

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Study Overview The study was designed as a phase 2b clinical trial to evaluate the efficacy and safety of rezpegaldesleukin

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study Read Post »

Reply to the Letter “Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barre Syndrome of a Severe Refractory Case”

Pathophysiology of Acute-Onset CIDP The pathophysiological mechanisms underlying Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are multifaceted and involve complex interactions

Reply to the Letter “Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barre Syndrome of a Severe Refractory Case” Read Post »

Scroll to Top